182 related articles for article (PubMed ID: 12200028)
1. Age-associated biomarker profiles of human breast cancer.
Eppenberger-Castori S; Moore DH; Thor AD; Edgerton SM; Kueng W; Eppenberger U; Benz CC
Int J Biochem Cell Biol; 2002 Nov; 34(11):1318-30. PubMed ID: 12200028
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical expression of uPA, PAI-1, cathepsin D and apoptotic cells in ductal carcinoma in situ of the breast.
Zhao H; Morimoto T; Sasa M; Tanaka T; Izumi K
Breast Cancer; 2002; 9(2):118-26. PubMed ID: 12016391
[TBL] [Abstract][Full Text] [Related]
3. Thrombospondin-1 and -2 in node-negative breast cancer: correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis.
Gasparini G; Toi M; Biganzoli E; Dittadi R; Fanelli M; Morabito A; Boracchi P; Gion M
Oncology; 2001; 60(1):72-80. PubMed ID: 11150912
[TBL] [Abstract][Full Text] [Related]
4. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].
Göhring UJ; Scharl A; Ahr A
Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
Foekens JA; Schmitt M; van Putten WL; Peters HA; Kramer MD; Jänicke F; Klijn JG
J Clin Oncol; 1994 Aug; 12(8):1648-58. PubMed ID: 8040677
[TBL] [Abstract][Full Text] [Related]
6. [Cytosolic pS2 levels and cellular proliferation in ER-positive and PgR-positive infiltrating ductal carcinomas of the breast].
Sánchez Salmón A; Argibay S; Arias JI; Ruibal A
Rev Esp Med Nucl; 2005; 24(3):185-90. PubMed ID: 15847785
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of tumor biological factors on survival in node-negative breast cancer.
Harbeck N; Dettmar P; Thomssen C; Henselmann B; Kuhn W; Ulm K; Jänicke F; Höfler H; Graeff H; Schmitt M
Anticancer Res; 1998; 18(3C):2187-97. PubMed ID: 9703782
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
[TBL] [Abstract][Full Text] [Related]
9. Age-dependent changes in breast cancer hormone receptors and oxidant stress markers.
Quong J; Eppenberger-Castori S; Moore D; Scott GK; Birrer MJ; Kueng W; Eppenberger U; Benz CC
Breast Cancer Res Treat; 2002 Dec; 76(3):221-36. PubMed ID: 12462383
[TBL] [Abstract][Full Text] [Related]
10. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients.
Eppenberger U; Kueng W; Schlaeppi JM; Roesel JL; Benz C; Mueller H; Matter A; Zuber M; Luescher K; Litschgi M; Schmitt M; Foekens JA; Eppenberger-Castori S
J Clin Oncol; 1998 Sep; 16(9):3129-36. PubMed ID: 9738585
[TBL] [Abstract][Full Text] [Related]
11. Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse.
Harbeck N; Thomssen C; Berger U; Ulm K; Kates RE; Höfler H; Jänicke F; Graeff H; Schmitt M
Breast Cancer Res Treat; 1999 Mar; 54(2):147-57. PubMed ID: 10424405
[TBL] [Abstract][Full Text] [Related]
12. [Expression of epidermal growth factor receptor (EGFR) in hormone-independent breast cancers].
Ruibal A; Garrido-Pumar M; Arias JI
Rev Esp Med Nucl; 2006; 25(1):15-9. PubMed ID: 16540006
[TBL] [Abstract][Full Text] [Related]
13. Clinical response to primary letrozole therapy in elderly patients with early breast cancer: possible role for p53 as a biomarker.
Garimella V; Hussain T; Agarwal V; Radhakrishna S; Fox JN; Kneeshaw PJ; Long ED; Mahapatra TK; McManus PL; Lind MJ; Drew PJ; Cawkwell L
Int J Surg; 2014; 12(8):821-6. PubMed ID: 25010604
[TBL] [Abstract][Full Text] [Related]
14. Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation.
Nakopoulou L; Stefanaki K; Panayotopoulou E; Giannopoulou I; Athanassiadou P; Gakiopoulou-Givalou H; Louvrou A
Hum Pathol; 2002 Sep; 33(9):863-70. PubMed ID: 12378509
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinase expression in human breast cancer: an immunohistochemical study including correlation with cathepsin D, type IV collagen, laminin, fibronectin, EGFR, c-erbB-2 oncoprotein, p53, steroid receptors status and proliferative indices.
Ioachim EE; Athanassiadou SE; Kamina S; Carassavoglou K; Agnantis NJ
Anticancer Res; 1998; 18(3A):1665-70. PubMed ID: 9673387
[TBL] [Abstract][Full Text] [Related]
17. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
Foekens JA; Look MP; Peters HA; van Putten WL; Portengen H; Klijn JG
J Natl Cancer Inst; 1995 May; 87(10):751-6. PubMed ID: 7563153
[TBL] [Abstract][Full Text] [Related]
18. Can axillary dissection be avoided by improved molecular biological diagnosis?
Lindahl T; Engel G; Ahlgren J; Klaar S; Bjöhle J; Lindman H; Andersson J; von Schoultz E; Bergh J
Acta Oncol; 2000; 39(3):319-26. PubMed ID: 10987228
[TBL] [Abstract][Full Text] [Related]
19. MIB1 proliferation index in breast infiltrating carcinoma: comparison with other proliferative markers and association with new biological prognostic factors.
González-Vela MC; Garijo MF; Fernández F; Val-Bernal JF
Histol Histopathol; 2001 Apr; 16(2):399-406. PubMed ID: 11332695
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
Järvinen TA; Holli K; Kuukasjärvi T; Isola JJ
Br J Cancer; 1998 Jun; 77(12):2267-73. PubMed ID: 9649144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
